Medical disclaimer: This page is educational information for people already working with a doctor on GLP-1 medication. Nothing here constitutes medical advice, prescribes dosing, or replaces the guidance of your treating physician. Always coordinate changes to medication, diet, and exercise with your doctor. GLP-1 medications are prescription medicines; consult a licensed UAE healthcare provider.
Why GLP-1 medications cause muscle loss — and why it matters
GLP-1 receptor agonists — including tirzepatide (Mounjaro) and semaglutide (Ozempic, Wegovy) — work primarily by suppressing appetite and slowing gastric emptying. The result is a significant calorie deficit that produces rapid weight loss. In clinical trials, tirzepatide produced average weight losses of approximately 20.2% of bodyweight; semaglutide approximately 13.7% (PMC12151102).
The problem: in the absence of resistance training and adequate protein, studies report that 25–40% of the weight lost on GLP-1 medications is lean mass — muscle, not fat. This figure is cited in multiple clinical reviews and reported in detail across peer-reviewed and clinical literature (Healthline, U.S. News Health). For context: a person losing 20 kg on GLP-1 without a muscle-preservation protocol could lose 5–8 kg of muscle alongside 12–15 kg of fat.
Why this matters beyond aesthetics:
- Resting metabolic rate drops. Muscle burns more calories at rest than fat tissue. Losing muscle lowers the number of calories your body needs to maintain weight — making rebound after stopping far more likely.
- Strength and function decline. Muscle loss accelerates the sarcopenia (~1%/year muscle loss after age 40) that affects every adult — GLP-1-driven muscle loss compounds it.
- Long-term body composition. A person who reaches their goal weight with low muscle will have a “soft” composition even at a lower scale number — the transformation looks incomplete.
For clients using GLP-1 medications, PTD’s at-home training and nutrition coaching can support muscle preservation alongside your doctor’s care. The doctor manages the prescription; a coach can support the training and protein side of the equation.
The muscle-preservation protocol: what actually works
The research on muscle preservation during GLP-1 use converges on three interventions. All three need to run simultaneously.
1. Protein target: 1.6–2.0 g/kg of bodyweight per day
This is the most important single variable. The ISSN protein position stand (PMC5477153) establishes 1.6–2.0 g/kg as the evidence-based range for preserving and building muscle in resistance-trained individuals. In a GLP-1-driven deficit, targeting the upper end (2.0 g/kg) provides the greatest muscle-sparing effect.
Practical targets:
| Bodyweight | Minimum (1.6 g/kg) | Target (2.0 g/kg) |
|---|---|---|
| 70 kg | 112 g/day | 140 g/day |
| 85 kg | 136 g/day | 170 g/day |
| 100 kg | 160 g/day | 200 g/day |
Hitting these targets when appetite is suppressed is one of the biggest practical challenges on GLP-1s. See the protein-on-a-suppressed-appetite section below.
2. Resistance training: 2–3 sessions per week
Cardio burns calories; resistance training sends the biological signal to retain muscle. Without that signal, your body treats muscle as expendable fuel during a large calorie deficit. A minimum of 2 full-body resistance sessions per week is the evidence-based floor for muscle preservation — 3 sessions per week is the target.
For GLP-1 users who are new to resistance training, at-home sessions that require no gym and scale from beginner to intermediate are a practical option — particularly when energy and motivation are low. See the build muscle guide for the full training framework.
3. Keep weekly loss at or below ~1% of bodyweight
The faster the scale drops, the higher the proportion of that loss that comes from muscle. A loss rate of more than 1% of bodyweight per week consistently shows higher lean-mass loss in the literature. On GLP-1 medications this can be harder to control — your doctor may adjust dose timing, while a coach can support with calorie targets, protein-front-loading, and training load adjustments to help moderate the rate.
If you are losing 2–3% of bodyweight weekly, the muscle-loss risk is significant — this is worth raising with your prescribing doctor.
Tracking lean mass: why the scale is not enough
Scale weight alone cannot tell you whether you are losing fat or muscle. A well-structured GLP-1 programme should track lean mass separately from fat mass at regular intervals.
STYKU 3D body composition scanning — available through PTD at the free assessment and at regular check-ins — gives a fat-mass and lean-mass split, not just a total weight. If lean mass is declining, the protocol can be adjusted immediately (protein and training volume increased) rather than after weeks of undetected muscle loss.
InBody scanning (available at many Dubai clinics and gyms) provides the same lean-mass/fat-mass split if STYKU is not accessible.
Book a free assessment to establish your lean-mass baseline before or during GLP-1 medication.
Training when appetite and energy are low
The most common barrier to resistance training on GLP-1 medications is not motivation — it is low energy from reduced calorie intake, and nausea during the first weeks on a new dose.
A practical weekly training structure around GLP-1 phases:
- High-energy days (typically mid-week, away from injection day): full resistance session, normal volume and intensity. This is when compound lifts — squats, rows, presses — are programmed.
- Low-energy days (typically 1–2 days post-injection): reduced-volume maintenance session. 3–4 exercises, 2–3 sets each, at 60–70% of normal intensity. The goal is to maintain the muscle-retention signal — not to push performance.
- Nausea management: avoid training within 1–2 hours of eating. Lighter resistance work (bands, bodyweight) is better tolerated on nauseous days than heavy compound loading.
A sample weekly structure for a GLP-1 user injecting weekly:
| Day | Training |
|---|---|
| Monday | Full-body resistance (injection day or day after — rest if severe nausea) |
| Tuesday | Rest or 20-min walk |
| Wednesday | Full-body resistance (typically highest energy — priority session) |
| Thursday | Rest |
| Friday | Upper or lower body resistance (moderate) |
| Saturday | Rest or light activity |
| Sunday | Rest |
This template is adjusted individually based on energy patterns across the first 4 weeks — a coach can help adapt the schedule to your injection timing and energy fluctuations.
Eating enough protein when you can barely eat
A suppressed appetite is the mechanism that makes GLP-1s work — and the biggest obstacle to hitting protein targets. The strategy is to front-load protein into every eating occasion, however small, before any other macronutrient.
Practical approaches:
- Protein-first every meal: eat protein before carbohydrates or fats. Chicken, eggs, Greek yoghurt, or cottage cheese as the first bite — not the last.
- Liquid protein when solid food is unappealing: Greek yoghurt blended with protein powder, skyr, or a high-quality protein shake (25–30 g protein, low volume) can hit 30+ g when eating solid food feels difficult.
- Smaller, more frequent protein hits: if two meals is all you can manage, aim for 40–50 g of protein at each. Prioritise protein over carbohydrates in those windows.
- Halal high-protein options in Dubai that are easy to eat in small amounts: Greek yoghurt, labneh, eggs, canned tuna, chicken strips, cottage cheese, protein-enriched dairy.
For a complete Dubai-specific halal nutrition guide including meal-prep options and eating out strategies, see nutrition.
Keeping your results after stopping GLP-1 medication
Stopping Mounjaro or Ozempic without a supporting lifestyle infrastructure leads to significant weight regain in the majority of users. This is the most consequential phase of the GLP-1 journey — and the most under-supported.
The off-ramp framework:
-
Build the muscle baseline during the medication phase. The higher your lean mass when you stop, the higher your resting metabolic rate — and the easier weight maintenance becomes. This is the single most important thing you can do while on GLP-1s.
-
Establish consistent resistance training as a habit. The goal is that training is so embedded in your routine by the time you stop that it continues automatically — not dependent on the medication for motivation.
-
Reverse diet after stopping. When appetite returns, calories should be raised gradually (100–150 kcal/week) to a maintenance level, not back to the previous high-calorie norm. This prevents the rapid intake spike that drives rebound.
-
Continue protein habits. The 1.6–2.0 g/kg protein target is a permanent maintenance tool, not just a medication-phase measure.
-
Monitor lean mass. A STYKU or InBody re-scan 4–6 weeks after stopping confirms whether composition is being maintained.
The risk of rebound is real. The mitigation is building enough metabolic and muscular infrastructure during the medication phase that the body can maintain the new composition without the drug — all alongside your doctor’s medical care.
Medical disclaimer: The information on this page is educational and is not a substitute for medical advice from a qualified healthcare provider. GLP-1 medications (tirzepatide/Mounjaro, semaglutide/Ozempic, Wegovy) are prescription medicines. Dosing, safety, suitability, and medical management must be handled by a licensed UAE physician. PTD Fitness provides exercise and nutrition coaching as a complement to — not a replacement for — medical supervision. Always coordinate with your doctor before changing exercise or nutrition during GLP-1 therapy.
Individual results vary.
Related articles
- Ozempic vs Mounjaro for weight loss — what the research shows
- How to keep weight off after stopping Mounjaro — the off-ramp protocol
For clients using GLP-1 medications who want support with training and nutrition, talk to a PTD coach — we can establish your lean-mass baseline with STYKU 3D scanning and structure a training and protein plan around your medication schedule and energy patterns.
